StockData
Kyntra Bio, Inc. logo

Kyntra Bio, Inc. (KYNB) stock

KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$2.04−1.16 (-36.25%)

Close on Nov 17, 2026Market cap $8.26MP/E 0.0Yield –

Kyntra Bio r&d expenses

Research and development expenses are spending on new products and technology.

Kyntra Bio's R&D Expenses for the twelve months ending Jun 30, 2026 was $22.86M, down 45.4% year over year. For fiscal 2025 it was $23.52M, down 75.4% from the year before. Over ten years it grew -19.8% a year on average. The highest annual figure on record is $387.04M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$23.52M-75.4%
FY2024Dec 31, 2024$95.69M-64.1%
FY2023Dec 31, 2023$266.47M-10.2%
FY2022Dec 31, 2022$296.79M-23.3%
FY2021Dec 31, 2021$387.04M+53.0%
FY2020Dec 31, 2020$252.92M+20.9%
FY2019Dec 31, 2019$209.27M-11.3%
FY2018Dec 31, 2018$235.84M+20.0%
FY2017Dec 31, 2017$196.52M+5.0%
FY2016Dec 31, 2016$187.21M-12.6%
FY2015Dec 31, 2015$214.09M+42.0%
FY2014Dec 31, 2014$150.79M+75.9%
FY2013Dec 31, 2013$85.71M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$6.82M+16.3%
Q1 FY2026Mar 31, 2026$7.57M-17.5%
Q4 FY2025Dec 31, 2025$7.27M+5.8%
Q3 FY2025Sep 30, 2025$1.21M-93.9%
Q2 FY2025Jun 30, 2025$5.87M-81.9%
Q1 FY2025Mar 31, 2025$9.18M-74.9%
Q4 FY2024Dec 31, 2024$6.87M-80.6%
Q3 FY2024Sep 30, 2024$19.97M-67.4%
Q2 FY2024Jun 30, 2024$32.36M-66.1%
Q1 FY2024Mar 31, 2024$36.49M-51.0%
Q4 FY2023Dec 31, 2023$35.32M-42.7%
Q3 FY2023Sep 30, 2023$61.19M-18.6%
Q2 FY2023Jun 30, 2023$95.48M+34.5%
Q1 FY2023Mar 31, 2023$74.49M-16.3%
Q4 FY2022Dec 31, 2022$61.63M-45.9%
Q3 FY2022Sep 30, 2022$75.18M-0.9%
Q2 FY2022Jun 30, 2022$70.96M-42.1%
Q1 FY2022Mar 31, 2022$89.02M+19.2%
Q4 FY2021Dec 31, 2021$113.92M+45.8%
Q3 FY2021Sep 30, 2021$75.88M+29.8%
Q2 FY2021Jun 30, 2021$122.57M+99.6%
Q1 FY2021Mar 31, 2021$74.68M+36.0%
Q4 FY2020Dec 31, 2020$78.13M+37.6%
Q3 FY2020Sep 30, 2020$58.48M+17.0%
Q2 FY2020Jun 30, 2020$61.41M+18.1%
Q1 FY2020Mar 31, 2020$54.90M+8.7%
Q4 FY2019Dec 31, 2019$56.80M-19.2%
Q3 FY2019Sep 30, 2019$49.96M-11.5%
Q2 FY2019Jun 30, 2019$52.01M-0.2%
Q1 FY2019Mar 31, 2019$50.50M-11.4%
Q4 FY2018Dec 31, 2018$70.28M+34.0%
Q3 FY2018Sep 30, 2018$56.44M+12.1%
Q2 FY2018Jun 30, 2018$52.14M+11.0%
Q1 FY2018Mar 31, 2018$56.97M+21.9%
Q4 FY2017Dec 31, 2017$52.47M+3.7%
Q3 FY2017Sep 30, 2017$50.34M+24.1%
Q2 FY2017Jun 30, 2017$46.98M–
Q1 FY2017Mar 31, 2017$46.73M–
Q4 FY2016Dec 31, 2016$50.61M–
Q3 FY2016Sep 30, 2016$40.56M–

More Kyntra Bio figures

See a number that looks wrong?